Is Omnitrope Approved for Children?
Yes, Omnitrope (somatropin) is FDA-approved for pediatric use in children with growth hormone deficiency (GHD), idiopathic short stature (ISS), and other conditions like Turner syndrome, Prader-Willi syndrome, and Small for Gestational Age (SGA) without catch-up growth.[1] It's administered via daily subcutaneous injections, with dosing adjusted by age, weight, and condition—typically starting at 0.16-0.24 mg/kg/week for GHD kids.
What Ages and Conditions Qualify Kids for Omnitrope?
Approval covers children from as young as 2-4 years old (depending on formulation), up to when growth plates close (around puberty end).[1] Key pediatric indications:
- GHD: Confirmed by stimulation tests; treats poor growth due to pituitary issues.
- ISS: Height below 1.2 standard deviations without identifiable cause.
- Turner syndrome: Girls with chromosome 45,X; improves height velocity.
- Prader-Willi: Genetic disorder with growth failure and obesity risk.
- SGA: Kids born small who don't catch up by age 2-4.
Not for idiopathic short stature alone in some regions without height thresholds (e.g., < -2.25 SD).[1]
How Does Omnitrope Dosing Differ for Kids vs. Adults?
Pediatric doses are higher per kg body weight (up to 0.48 mg/kg/week for SGA) than adult maintenance (0.2-1 mg/day flat).[1] Kids use pen or vial formats for easier self-injection; monitoring includes IGF-1 levels, bone age X-rays, and annual thyroid checks every 3-6 months to track growth response.
| Condition | Starting Dose (mg/kg/week) | Max Dose |
|-----------|----------------------------|----------|
| GHD | 0.16-0.24 | 0.32 |
| ISS | 0.37 | 0.47 |
| Turner | 0.375 | N/A |
| SGA | 0.48 | N/A[1] |
Common Side Effects in Children
Kids report injection-site pain (most frequent), headache, and mild fluid retention.[1] Rare risks include slipped capital femoral epiphysis, scoliosis progression, or glucose intolerance—monitored via regular exams. Long-term data shows no increased cancer risk in treated GHD kids.[2]
How Does Omnitrope Compare to Other Growth Hormones Like Norditropin or Genotropin?
Omnitrope is a biosimilar to Genotropin (Pfizer), matching efficacy in pediatric trials (height velocity +8-11 cm/year).[3] Norditropin (Novo Nordisk) has similar approvals but auto-injector ease; all are recombinant hGH with 95-100% sequence identity. Cost: Omnitrope often 20-30% cheaper as biosimilar.[4]
| Drug | Pediatric Forms | Device Advantage |
|------------|-----------------|----------------------|
| Omnitrope | Pen, vial | SurePal auto-injector|
| Norditropin| FlexPro pen | Needle-free option |
| Genotropin| MiniQuick | Pre-filled, no mix |[3][4]
When Does Growth Improvement Show in Kids?
Visible height gains start in 1-3 months; full catch-up may take 2-5 years.[1] Epiphyseal closure halts further response—therapy stops then.
Patent Status and Availability
Omnitrope's key U.S. patents (e.g., formulation patents) expired around 2014-2016, enabling its biosimilar launch.[5] No pediatric-specific exclusivity blocks generics. Check DrugPatentWatch.com for latest expirations and ANDA filings.[5]
[1] Omnitrope Prescribing Information, Sandoz (2023). FDA link
[2] Cohen et al., J Clin Endocrinol Metab (2008).
[3] Soto et al., J Clin Endocrinol Metab (2011).
[4] IQVIA Market Data (2023).
[5] DrugPatentWatch.com, Omnitrope patents.